First Republic Investment Management, Inc. Heron Therapeutics, Inc. Transaction History

First Republic Investment Management, Inc.

$34.7 Billion
Q3 2023

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 11, 2023	SELL	$1.51 - $3.25 $4,736 - $10,195	-3,137 Reduced 5.19%	57,353 $86,000
Q4 2022 Feb 13, 2023	BUY	$2.25 - $4.67 $19,010 - $39,456	8,449 Added 16.24%	60,490 $151,000
Q3 2022 Nov 03, 2022	BUY	$2.66 - $5.37 $19,915 - $40,205	7,487 Added 16.8%	52,041 $220,000
Q2 2022 Aug 16, 2022	SELL	$2.3 - $6.29 $6,462 - $17,674	-2,810 Reduced 5.93%	44,554 $124,000
Q1 2022 May 16, 2022	SELL	$4.63 - $9.94 $9,667 - $20,754	-2,088 Reduced 4.22%	47,364 $271,000
Q4 2021 Feb 09, 2022	BUY	$8.35 - $12.6 $61,439 - $92,710	7,358 Added 17.48%	49,452 $451,000
Q3 2021 Nov 12, 2021	BUY	$10.13 - $15.0 $54,448 - $80,625	5,375 Added 14.64%	42,094 $450,000
Q2 2021 Aug 16, 2021	BUY	$13.27 - $18.48 $185,275 - $258,017	13,962 Added 61.35%	36,719 $570,000
Q1 2021 May 14, 2021	BUY	$14.49 - $20.72 $100,082 - $143,113	6,907 Added 43.58%	22,757 $369,000
Q3 2020 Nov 12, 2020	BUY	$13.67 - $17.77 $17,948 - $23,332	1,313 Added 9.03%	15,850 $235,000
Q2 2020 Aug 13, 2020	BUY	$10.89 - $21.47 $158,307 - $312,109	14,537 New	14,537 $214,000

Others Institutions Holding HRTX

# of Institutions

180

Shares Held

121M

Call Options Held

80.4K

Put Options Held

94.9K

Rubric Capital Management LP New York, NY

26.7M
Shares

$29.9 Million
1.48% of portfolio
Adage Capital Partners Gp, L.L.C. Boston, MA

8.85M
Shares

$9.91 Million
0.03% of portfolio
Vanguard Group Inc Valley Forge, PA

8.72M
Shares

$9.77 Million
0.0% of portfolio
Black Rock Inc. New York, NY

8.33M
Shares

$9.32 Million
0.0% of portfolio
Velan Capital Investment Management LP Alpharetta, GA

6.99M
Shares

$7.83 Million
28.8% of portfolio

View Full List

About HERON THERAPEUTICS, INC.

Ticker HRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 118,774,000
Market Cap $133M
Description
Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet patient needs. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single a...

More about HRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of First Republic Investment Management, Inc., based on Form 13F filings with the SEC.

News

Stay updated on First Republic Investment Management, Inc. with notifications on news.

Account